Bayer adj EBITDA jumps 33 pct on higher drug sales, forex gains

July 29, 2015 5:55 AM

24 0

FRANKFURT, July 29 German drugmaker Bayer saw underlying core earnings increase by one third in the second quarter, helped by strong overseas currencies and a gain in prescriptions of new drugs such a stroke prevention pill Xarelto.

Second-quarter adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) rose to 2.90 billion euros ($3.21 billion), compared with market expectations of 2.68 billion euros, while quarterly revenue gained 18 percent to 12.09 billion, also beating the analyst consensus.

Read more

To category page